The Cologuard Plus test is being offered as an in-network service to eligible Humana Medicare Advantage members.

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Exact Sciences (EXAS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results ...

Exact Sciences is also developing blood-based tests to help in multi-cancer and MRD screening. The company has been actively engaging in M&A to support the development of these new products.

On March 3, 2020, Exact Sciences announced completion of its acquisition of Paradigm Diagnostics, Inc. and Viomics, Inc., privately held companies based in Phoenix, AZ. According to Exact Sciences ...

Exact Sciences plans to launch the new product in the second half of 2020. Exact Sciences thinks that it now has a total addressable market of $20 billion.

About Exact Sciences A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier.

Exact Sciences is expected to maintain strong growth on top of FYE 2020 revenues of $1.49B and a 3-year expected CAGR of 20%, albeit down from 2017-2020's growth CAGR of >75%.

Exact Sciences Corporation (NASDAQ:EXAS) is one of the best mid cap pharma stocks to buy. On July 9, Exact Sciences announced ...

Exact Sciences, the maker of at-home colon cancer screening test Cologuard, said it will buy Cambridge, Massachusetts-based Thrive Earlier Detection Corp. for $2.15 billion in cash and stock.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial ...

Key Points Exact Sciences has the potential to be a big name in cancer testing and screening in the future. It already has multiple tests, and is working on one that can screen for multiple cancers.